Advanced search
Publication Cover
International Journal of Nanomedicine Volume 14, 2019 - Issue
Submit an article Journal homepage
180
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study

Chan Wu1 Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, People’s Republic of China, [email protected]; [email protected]
,
Yang Zhang1 Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, People’s Republic of China, [email protected]; [email protected];2 Department of Pharmacy, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, People’s Republic of China
,
Daoqiu Yang3 Department of Dermatology, 107th Hospital of PLA, Yantai 264000, People’s Republic of China
,
Jinfeng Zhang4 Department of Traditional Chinese Medicine, Shanghai Hospital of Chinese Integrative Medicine, Shanghai, People’s Republic of China
,
Juanjuan Ma1 Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, People’s Republic of China, [email protected]; [email protected]
,
Dan Cheng1 Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, People’s Republic of China, [email protected]; [email protected]
,
Jianming Chen1 Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, People’s Republic of China, [email protected]; [email protected]Correspondence[email protected] [email protected]
&
Li Deng1 Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, People’s Republic of China, [email protected]; [email protected]Correspondence[email protected] [email protected]
 show all
Pages 75-85 | Published online: 20 Dec 2018

References

  • WallMEWaniMCCookCEPalmerKHMcphailATSimGAPlant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2J Am Chem Soc1966881638883890
  • KawatoYAonumaMHirotaYKugaHSatoKIntracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11Cancer Res19915116418741911651156
  • MonterrubioCPascual-PastoGCanoFSN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgeryBiomaterials201679697826695118
  • LuJLiuCWangPThe self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecinBiomaterials20156217618726057133
  • BalaVRaoSBoydBJPrestidgeCAProdrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38J Control Release20131721486123928356
  • IyerRCroucherJLChornyMNanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastomaCancer Lett2015360220521225684664
  • SlatterJGSchaafLJSamsJPPharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C] CPT-11 in cancer patientsDrug Metab Dispos200028442343310725311
  • ZhaoHRubioBSapraPNovel prodrugs of SN38 using multiarm poly(ethylene glycol) linkersBioconjug Chem200819484985918370417
  • ZhangHWangJMaoWNovel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studiesJ Control Release2013166214715823266448
  • SadekarSThiagarajanGBartlettKPoly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecinInt J Pharm2013456117518523933439
  • OmarRBardoogoYLCorem-SalkmonEMizrahiBAmphiphilic star PEG-Camptothecin conjugates for intracellular targetingJ Control Release2017257768327677603
  • XieJZhangXTengMSynthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapyInt J Nanomedicine2016111677168627217746
  • SepehriNRouhaniHTavassolianFSN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecanInt J Pharm20144711–248549724879937
  • PalakurthiSChallenges in SN38 drug delivery: current success and future directionsExpert Opin Drug Deliv201512121911192126206312
  • BotellaPRivero-BucetaESafe approaches for camptothecin delivery: Structural analogues and nanomedicinesJ Control Release2017247285428027948
  • OlusanyaTOBHaj AhmadRRIbegbuDMSmithJRElkordyAALiposomal Drug Delivery Systems and Anticancer DrugsMolecules2018234E90729662019
  • AllenTMCullisPRLiposomal drug delivery systems: from concept to clinical applicationsAdv Drug Deliv Rev2013651364823036225
  • SadzukaYTakabeHSonobeTLiposomalization of SN-38 as active metabolite of CPT-11J Control Release20051082–345345916182400
  • CiTLiTChangGYuLDingJSimply mixing with poly(ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin familyJ Control Release2013169332933523246468
  • SafraTMuggiaFJeffersSPegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2Ann Oncol20001181029103311038041
  • FangTDongYZhangXXieKLinLWangHIntegrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumorsInt J Pharm20165121394827544846
  • ParkJWLiposome-based drug delivery in breast cancer treatmentBreast Cancer Res200243959912052251
  • YangXZhaoXPhelpsMAA novel liposomal formulation of flavopiridolInt J Pharm20093651–217017418778761
  • NiiTIshiiFEncapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle methodInt J Pharm2005298119820515951143
  • AlferievISIyerRCroucherJLNanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapyBiomaterials201551222925770994
  • GoffLWBensonAB3rdLoRussoPMPhase I study of oral irinotecan as a single-agent and given sequentially with capecitabineInvest New Drugs201230129029820857171
  • SchoemakerNEKuppensIEHuininkWWPhase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumoursCancer Chemother Pharmacol200555326327015592838
  • SignorellRDLucianiPBrambillaDLerouxJCPharmacokinetics of lipid-drug conjugates loaded into liposomesEur J Pharm Biopharm201812818819929678733
  • LeePCChiouYCWongJMPengCLShiehMJTargeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibodyBiomaterials201334348756876523937913

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.